Cargando…

Antibody formation against SARS-CoV-2 in imatinib-treated COVID-19 patients

Detalles Bibliográficos
Autores principales:	Morales-Ortega, Alejandro, Farfán-Sedano, Ana Isabel, Izquierdo-Martínez, Aida, Llarena-Barroso, Cristina, Jaenes-Barrios, Beatriz, Mesa-Plaza, Nieves, Toledano-Macías, María, Soria Fernández-Llamazares, Guillermo, Molina-Esteban, Laura, García de Tena, Jaime, Prieto-Menchero, Santiago, Gonzalo-Pascua, Sonia, San Martín-López, Juan Víctor, Bernal-Bello, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381632/ https://www.ncbi.nlm.nih.gov/pubmed/34437930 http://dx.doi.org/10.1016/j.jinf.2021.08.034

Ejemplares similares

Imatinib in COVID-19: hope and caution
por: Bernal-Bello, David, et al.
Publicado: (2021)

Early clinical experience with imatinib in COVID-19: Searching for a dual effect
por: Morales-Ortega, Alejandro, et al.
Publicado: (2021)

Imatinib for COVID-19: A case report
por: Morales-Ortega, Alejandro, et al.
Publicado: (2020)

Imatinib might constitute a treatment option for lung involvement in COVID-19
por: Bernal-Bello, David, et al.
Publicado: (2020)

Comparative Study of Vaccinated and Unvaccinated Hospitalised Patients: A Retrospective Population Study of 500 Hospitalised Patients with SARS-CoV-2 Infection in a Spanish Population of 220,000 Inhabitants
por: Ruiz-Giardin, José M., et al.
Publicado: (2022)

Seven Epidemic Waves of COVID-19 in a Hospital in Madrid: Analysis of Severity and Associated Factors
por: San Martín-López, Juan Víctor, et al.
Publicado: (2023)

Laboratorio clínico : principios generales
por: Prieto Menchero, Santiago
Publicado: (1993)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

Effects of exchange vs. controlled diet on biochemical, body composition and functional parameters in elite female soccer players
por: San Atanasio, Sandra Antón, et al.
Publicado: (2023)

The pharmacogenetics of imatinib
por: Dulucq, Stéphanie, et al.
Publicado: (2010)

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
por: Kumar, Rajiv, et al.
Publicado: (2017)

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate
por: Pautier, Patricia, et al.
Publicado: (2013)

Optical Methods Based on Ultraviolet, Visible, and Near-Infrared Spectra to Estimate Fat and Protein in Raw Milk: A Review
por: Gastélum-Barrios, Abraham, et al.
Publicado: (2020)

Exploiting the promiscuity of imatinib
por: Lee, Shun J, et al.
Publicado: (2009)

Imatinib-induced pancreatitis
por: Varma, Mahesh R., et al.
Publicado: (2010)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Imatinib Use in Pregnancy
por: Webb, Michael J, et al.
Publicado: (2012)

Imatinib-Induced Psoriasis
por: Atalay, Figen, et al.
Publicado: (2013)

The Side Effects of Imatinib
por: Uzer, Elmas, et al.
Publicado: (2013)

Imatinib-induced Gynecomastia
por: Gupta, Pragya, et al.
Publicado: (2019)

The Effect of Apigenin on Pharmacokinetics of Imatinib and Its Metabolite N-Desmethyl Imatinib in Rats
por: Liu, Xian-yun, et al.
Publicado: (2013)

Giving imatinib a hand
por: Maxmen, Amy
Publicado: (2008)

IMATINIB INDUCED LICHEN PLANUS
por: Sudha, R, et al.
Publicado: (2011)

Correction: Exploiting the promiscuity of imatinib
por: Lee, Shun J, et al.
Publicado: (2010)

Imatinib in the treatment of dermatofibrosarcoma protuberans
por: Labropoulos, Stefanos V, et al.
Publicado: (2007)

Therapeutic drug monitoring of imatinib
por: Wallemacq, Pierre
Publicado: (2011)

Imatinib activity on Schistosoma mansoni
por: Katz, Naftale, et al.
Publicado: (2013)

Eyebrow Whitening Induced by Imatinib
por: Yavasoglu, Irfan, et al.
Publicado: (2020)

Imatinib: Rhabdomyolysis: case report
Publicado: (2020)

DRESS syndrome induced by imatinib
por: Kaur, S, et al.
Publicado: (2021)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
por: Lee, Min Kyung, et al.
Publicado: (2015)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Letter to the Editor Regarding Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind
por: Bernal-Bello, David, et al.
Publicado: (2022)

Is there a cloud in the silver lining for imatinib?
por: Paterson, S C, et al.
Publicado: (2003)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Repositioning imatinib for spinal cord injury
por: Kjell, Jacob, et al.
Publicado: (2015)

Pharmacology and rationale for imatinib in the treatment of scleroderma
por: Moinzadeh, Pia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pv3tla565d37rah8fuc3i0tdpq